{
    "nct_id": "NCT03867097",
    "official_title": "A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis",
    "inclusion_criteria": "* Male or female subjects must be greater than or equal to 18 years of age\n* Subjects must have a diagnosis of Systemic Sclerosis\n* Subjects must have a diagnosis or history of Raynaud's Phenomenon\n* Subjects must have a minimum of 10 symptomatic Raynaud's Phenomenon attacks\n* Female subjects of childbearing potential and male subjects must agree to use contraception for the duration of the study\n* Subjects must be willing and able to comply with the study requirements and give informed consent for participation in the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Female subjects who are pregnant or breastfeeding\n* Subjects with systolic blood pressure <85 mmHg\n* Subjects with an estimated glomerular filtration rate <30 mL/min/1.73 m2\n* Subjects with Child-Pugh Class B or Class C liver disease or an alanine aminotransferase and/or aspartate aminotransferase value >3 Ã— the upper limit of normal at screening.\n* Subjects with gangrene, digital ulcer infection, or requirement of cervical or digital sympathectomy\n* Subjects with intractable diarrhea or vomiting\n* Subjects with a risk of clinically significant bleeding events including those with coagulation or platelet disorders\n* Subjects with a history of major trauma or hemorrhage\n* Subjects with clinically significant chronic intermittent bleeding such as active gastric antral vascular ectasia or active peptic ulcer disease\n* Subjects who have had any cerebrovascular events\n* Subjects with a history of myocardial infarction or unstable angina within 6 months of screening\n* Subjects with acute or chronic congestive heart failure\n* Subjects with a history of life-threatening cardiac arrhythmias\n* Subjects with a history of hemodynamically significant aortic or mitral valve disease\n* Subjects with more than mild restrictive or congestive cardiomyopathy uncontrolled by medication or implanted device.\n* Subjects with known pulmonary hypertension, pulmonary arterial hypertension, or pulmonary veno-occlusive disease\n* Subjects with a history of significant restrictive lung disease defined as forced vital capacity <45% predicted and diffusing capacity of the lungs for carbon monoxide <40% predicted (uncorrected for hemoglobin).\n* Subjects with a history of cervical or digital sympathectomy\n* Subjects with scleroderma renal crisis\n* Subjects with a concomitant life-threatening disease with a life expectancy <12 months\n* Subjects who have a clinically significant disorder, that in the opinion of the Investigator, could contraindicate the administration of study drug, affect compliance, interfere with study evaluations, or confound the interpretation of study results\n* Subjects who have taken or are currently taking any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonists\n* Subjects must not initiate dosing of oral, topical, or intravenous (IV) vasodilators or if currently receiving any vasodilator must have been stably medicated\n* Subjects with any history of acetaminophen intolerability\n* Subjects with any malignancy that requires treatment during the study period, that has required treatment within 1 year of screening, or that is currently not in remission.\n* Subjects who have used any investigational medication or device for any indication within 30 days or 5 half-lives (whichever is longer)",
    "miscellaneous_criteria": ""
}